NCT05349201 is a clinical trial of KYMRIAH in Diffuse Large B-Cell Lymphoma (DLBCL), sponsored by Novartis Pharmaceuticals.

Who is sponsoring NCT05349201?

NCT05349201 is sponsored by Novartis Pharmaceuticals.

What drugs are being tested in NCT05349201?

Interventions in NCT05349201: KYMRIAH, YESCARTA.

What condition does NCT05349201 study?

NCT05349201 studies Diffuse Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL).

Is NCT05349201 still recruiting?

NCT05349201 is currently completed. Last updated 1 July 2022.

Last reviewed 2022-07-01 · How we verify

NCT05349201

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CAR T Cells Real World Evidence Study Based on the French Hospital Claims Data Source (PMSI)

Completed Last updated 1 July 2022

What this trial tests

trial testing KYMRIAH in Diffuse Large B-Cell Lymphoma (DLBCL) in 273 participants. Completed in 28 May 2021.

Timeline

9 December 2020

Primary endpoint
28 May 2021

28 May 2021

Quick facts

Lead sponsor	Novartis Pharmaceuticals
Status	Completed
Study type	OBSERVATIONAL
Enrollment	273
Start date	9 December 2020
Primary completion	28 May 2021
Estimated completion	28 May 2021
Sites	1 location across United States

Drugs / interventions tested

KYMRIAH — full drug profile →
YESCARTA — full drug profile →

Conditions studied

Diffuse Large B-Cell Lymphoma (DLBCL) — all drugs for Diffuse Large B-Cell Lymphoma (DLBCL) →
Acute Lymphoblastic Leukemia (ALL) — all drugs for Acute Lymphoblastic Leukemia (ALL) →

Sponsor

Novartis Pharmaceuticals — full company profile →

Who can join

Adults 18 to 30, any sex, with Diffuse Large B-Cell Lymphoma (DLBCL) or Acute Lymphoblastic Leukemia (ALL). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This was a Retrospective cohort study based on the PMSI data source

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of KYMRIAH

Trials testing the same drug.

NCT03642626 — MT2017-45: CAR-T Cell Therapy for Heme Malignancies · Phase 2 · active not recruiting

Other recruiting trials for Diffuse Large B-Cell Lymphoma (DLBCL)

Currently open trials in the same condition.

NCT07493109 — Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOP · Phase 3 · recruiting
NCT07493148 — Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL · Phase 2 · recruiting
NCT07397832 — CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL · Phase 2 · recruiting
NCT07499271 — Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation · Phase 2 · recruiting
NCT07189065 — A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma · Phase 2 · recruiting

Other Novartis Pharmaceuticals trials

Trials by the same sponsor.

NCT07498335 — Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary · Phase 3 · not yet recruiting
NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 4 · not yet recruiting
NCT07484269 — PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan · not yet recruiting
NCT07416162 — A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy · not yet recruiting
NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05349201 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novartis Pharmaceuticals
Last refreshed: 1 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05349201.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing